Researchers have uncovered inflammatory markers that may predict which COVID-19 patients are more likely to respond to therapies like the anti-cancer drug pacritinib, according to phase 2 trial results.
Brabus Launches ‘Deep Blue’ G-Wagon, Speedboat & Luxury Watch Line
Brabus is unifying its collaborations with Mercedes-AMG, Finland’s Axopar Boats, and Panerai luxury watches under one Deep Blue collection.Being that Brabus is...
